πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital β€” phase, modality, and trial IDs.

Programs
186

Quick answer

First People's Hospital has 186 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Optimal hypoglycemic treatment

    The First People's Hospital of Lianyungang

    Type2 Diabetes

    approved other active

    1 trial

  2. Ornithine aspartate granule

    The First People's Hospital of Lianyungang

    Non-alcoholic Fatty Liver Disease

    approved small molecule completed

    1 trial

  3. PCIA group

    The First People's Hospital of Lianyungang

    Postoperative Pain

    approved other active

    1 trial

  4. PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    approved small molecule active

    1 trial

  5. PEG-somatropin

    The First People's Hospital of Lianyungang

    Growth Hormone Deficiency

    approved mab active

    1 trial

  6. Parecoxib

    The First People's Hospital of Lianyungang

    Postoperative Pain Management, Pain Threshold, Shoulder Pain, Laparoscopies

    approved small molecule completed

    1 trial

  7. Parecoxib

    The First People's Hospital of Lianyungang

    Emergence Delirium

    approved small molecule active

    1 trial

  8. Pegylated liposomal doxorubicin

    The First People's Hospital of Lianyungang

    Breast Cancer

    approved small molecule active

    1 trial

  9. Pharmacotherapy

    The First People's Hospital of Lianyungang

    Diabetes Mellitus, Type 2

    approved small molecule active

    1 trial

  10. Pramipexole

    The First People's Hospital of Lianyungang

    Restless Legs Syndrome

    approved small molecule terminated

    1 trial

  11. Prothrombin Complex Concentrate, Human

    The First People's Hospital of Lianyungang

    Cardiac Surgical Procedures

    approved small molecule active

    1 trial

  12. Raltitrexed

    The First People's Hospital of Lianyungang

    Head and Neck Squamous Cell Carcinoma

    approved small molecule active

    1 trial

  13. Realgar-Indigo Naturalis Formulation Combined with Anlotinib

    The First People's Hospital of Lianyungang

    Platinum-resistant Ovarian Cancer (PROC)

    approved small molecule active

    1 trial

  14. Recaticimab

    The First People's Hospital of Lianyungang

    STEMI - ST Elevation Myocardial Infarction

    approved small molecule active

    1 trial

  15. Recaticimab and Statin

    The First People's Hospital of Lianyungang

    Intracranial Atherosclerosis

    approved small molecule active

    1 trial

  16. Recombinant Human Adenovirus Type 5 injection

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    approved small molecule active

    1 trial

  17. Recombinant Staphylokinase

    The First People's Hospital of Lianyungang

    ST-segment Elevation Myocardial Infarction (STEMI)

    approved small molecule completed

    1 trial

  18. Recombinant Staphylokinase

    The First People's Hospital of Lianyungang

    Acute Myocardial Infarction

    approved small molecule completed

    1 trial

  19. Recombinant staphylokinase

    The First People's Hospital of Lianyungang

    ST Elevation Myocardial Infarction

    approved small molecule active

    1 trial

  20. Remimazolam Besylate for Injection

    The First People's Hospital of Lianyungang

    Thoracic Surgery

    approved small molecule active

    1 trial

  21. Resveratrol

    The First People's Hospital of Lianyungang

    Pancreatitis, Acute

    approved small molecule active

    1 trial

  22. Rifaximin

    The First People's Hospital of Lianyungang

    IBS - Irritable Bowel Syndrome

    approved small molecule active

    1 trial

  23. Rituximab

    The First People's Hospital of Lianyungang

    Hemophagocytic Lymphohistiocytosis

    approved small molecule active

    1 trial

  24. Ropivacaine

    The First People's Hospital of Lianyungang

    Radius Fractures

    approved small molecule completed

    1 trial

  25. Ropivacaine

    The First People's Hospital of Lianyungang

    End Stage Renal Disease (ESRD)

    approved small molecule active

    1 trial

  26. Rosuvastatin

    The First People's Hospital of Lianyungang

    Hyperlipidemia

    approved small molecule active

    1 trial

  27. Rucacuzumab plus standard therapy

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke AIS

    approved small molecule active

    1 trial

  28. Ruxolitinib

    The First People's Hospital of Lianyungang

    Safety and Efficacy

    approved small molecule active

    2 trials

  29. S-1

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    approved small molecule active

    1 trial

  30. S-ketamine & Ropivacaine

    The First People's Hospital of Lianyungang

    Postoperative Analgesia

    approved small molecule active

    1 trial

  31. SGLT2 inhibitor

    The First People's Hospital of Lianyungang

    Type2 Diabetes

    approved small molecule active

    1 trial

  32. Sertraline

    The First People's Hospital of Lianyungang

    Efficacy, Team

    approved small molecule completed

    1 trial

  33. Sertraline Hydrochloride

    The First People's Hospital of Lianyungang

    COVID-19 Vaccine Adverse Reaction

    approved small molecule completed

    1 trial

  34. Shenfu Injection

    The First People's Hospital of Lianyungang

    Septic Shock

    approved small molecule active

    2 trials

  35. Skin stretching device (SSD)

    The First People's Hospital of Lianyungang

    Trauma

    approved other active

    1 trial

  36. Standard BP control

    The First People's Hospital of Lianyungang

    Hypertension

    approved small molecule active

    1 trial

  37. Statin

    The First People's Hospital of Lianyungang

    Acute Coronary Syndrome

    approved small molecule active

    1 trial

  38. Sufentanil

    The First People's Hospital of Lianyungang

    Arteriovenous Malformation

    approved small molecule active

    1 trial

  39. Tamsulosin Oral Capsule

    The First People's Hospital of Lianyungang

    Ischaemic Heart Disease (IHD)

    approved small molecule completed

    1 trial

  40. Tenofovir Alafenamide 25 MG

    The First People's Hospital of Lianyungang

    Chronic Hepatitis C

    approved small molecule active

    1 trial

  41. Tenofovir Alafenamide Tablets

    The First People's Hospital of Lianyungang

    Chronic Hepatitis b

    approved small molecule active

    1 trial

  42. Thalidomide

    The First People's Hospital of Lianyungang

    Gastric Cancer

    approved small molecule active

    1 trial

  43. Tirzepatide

    The First People's Hospital of Lianyungang

    Type 2 Diabetes Mellitus

    approved small molecule active

    1 trial

  44. Tislelizumab

    The First People's Hospital of Lianyungang

    Advanced NSCLC

    approved small molecule active

    1 trial

  45. Tislelizumab + cisplatin + paclitaxel

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    approved small molecule active

    1 trial

  46. Tocilizumab

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    approved small molecule active

    1 trial

  47. Tranexamic Acid

    The First People's Hospital of Lianyungang

    Postpartum Hemorrhage， Cesarean Section

    approved small molecule active

    1 trial

  48. Trastuzumab Rezetecan

    The First People's Hospital of Lianyungang

    Breast Cancer

    approved small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

186 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.